华兰生物 (002007)

Hualan Biological Engineering Inc.

ASZ

Tags

CSI 200 IndexBroker Heavy PositionsGene ConceptBiological ProductsBiological VaccinesHigh-Dividend Yield StocksShenzhen ConnectSZSE 300 IndexPharma & BiotechConsumer Services IndexSME Board Emerging IndexSZSE Medicine Equal Weight IndexZhongchuang Equal Weight IndexShenzhen A-Share Pharmaceutical IndexBOC International CSI 300 ESG IndexCCTV Innovation IndexCSI All-share Pharmaceutical Sector IndexEmerging Technology 100 IndexSZSE Emerging Industries IndexSZSE 1000 IndexSME Board Equal Weight IndexSZSE 300 Return IndexCSSW Health IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexCSI 300 ESG IndexLarge & Mid-cap IndexCSWD Life Sciences IndexCNI 1000 IndexBiomedicine IndexSME Board Value IndexZhongchuang Value IndexInfluenza/MaskNew Virus PreventionCOVID-19 PreventionHepatitis B VaccineFTSE Russell ConceptHuijin ConceptShareholding Increase CommitmentLarge-cap Blue-chipCentral Plains Economic ZoneAntiviralCSI 300 Non-cyclical IndexPension Industry IndexSME Board Composite IndexPublic Health IndexSZSE Selected IndexSZSE Responsibility IndexCS High-end Manufacturing IndexVaccine & Biotech IndexCSI 300 Shenzhen Market IndexZhongchuang 100 Return IndexSZSE Technology IndexCSI 300 ESG Leading IndexEmerging Industries Composite IndexSHS Innovative Drugs IndexSZSE ChiNext 100 IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI IndexCSI 300 Preferred IndexCCTV Governance IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCSI 300 USD (CNH) IndexSZSE Private Enterprises IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSmart Select 300 ESG Leading IndexSME Board Low Volatility IndexSZSE 300 Equal Weight IndexCSI Pharmaceutical IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightCS Biomedicine IndexPharmaceutical & Health 100 IndexCSI 300 Pharmaceutical IndexSME Board Performance IndexSME & ChiNext Q IndexCSI 700 IndexMid-small Cap IndexCSI 500 IndexPharmaceutical 50 IndexZhongchuang Low Volatility IndexPharmaceutical 50 Strategy IndexCSI Life Sciences IndexSZSE 200 Return IndexSZSE 200 IndexMid-cap Low Volatility IndexCICC 300 IndexZhongchuang 400 IndexCS Innovative Drugs IndexESG 300 IndexCR New Momentum IndexJuchao Mid-cap IndexCSI 1000 Value IndexFundamental 600 IndexStrategic Emerging Industries 100 Index

K-Line Chart

No K-line data available

Company NameHualan Biological Engineering Inc.
Listing Date2004-06-25
Issue Price15.74RMB
Registered Capital182745.666610k RMB
Legal RepresentativeAn Kang
Registered AddressNo. 1A, Hualan Avenue, Xinxiang City, Henan Province
IndustryBiological Products
Main BusinessSales of blood products such as Human Albumin, Intravenous Immunoglobulin, and Intramuscular Immunoglobulin.
Company ProfileHualan Biological Engineering Inc. (formerly Hualan Biological Engineering Co., Ltd.) was founded in 1992. It is a key high-tech enterprise engaged in the research, development, and production of blood products, and was the first in the blood products industry to pass GMP certification. As a designated large-scale biological products manufacturer by the state, the company possesses strong technological development capabilities, advanced technical levels, production and testing equipment, scientific and standardized operation management, and a comprehensive quality assurance system. The company has undertaken numerous national, provincial, and municipal scientific and technological research projects, among which the Lyophilized Human Fibrin Sealant for Surgical Use was included in the National 863 Program. The establishment of the Hualan Postdoctoral Research Station, the Henan Provincial Biomedical Engineering Technology Center, the CAS Biological Technology Innovation and Industrialization Joint Fund, and several joint laboratories with the Chinese Academy of Sciences has laid a solid foundation for the company's high growth and core competitiveness. Over the years, the company has maintained stable management and standardized operations, highlighting its core competitive strength through technological advantages. After nearly two decades of development, Hualan Biological currently has over thirty wholly-owned subsidiaries, with a total market capitalization exceeding 28 billion yuan. It offers a rich variety and complete specifications of blood products. Key financial indicators have shown continuous growth for many years.

Stock Details

1. Key Indicators

  • Total Shares(W): 182745.67
  • Circulating A-Shares(W): 157370.29
  • Earnings Per Share(RMB): 0.4291
  • Net Assets Per Share(RMB): 6.2228
  • Operating Revenue(W RMB): 337888.64
  • Total Profit(W RMB): 97241.42
  • Net Profit Attributable to Parent(W RMB): 78442.30
  • Net Profit Growth Rate(%): -15.07
  • Weighted Return on Equity(%): 6.5500
  • Operating Cash Flow Per Share(RMB): 0.2470
  • Undistributed Profit Per Share(RMB): 3.9619
  • Capital Reserve Per Share(RMB): 0.7795

2. Main Business

The main business covers:

  • Blood products
  • Vaccines
  • R&D, production and sales of genetic engineering products

3. Company Basic Information

  • Company Name: Hualan Biological Engineering, Inc.
  • Listing Date: 2004-06-25
  • Industry: Pharmaceutical Manufacturing
  • Address: No.1 A Hualan Avenue, Xinxiang City, Henan Province
  • Website: www.hualanbio.com
  • Company Profile: The company is a foreign-invested joint-stock company established through the overall transformation of Hualan Biological Engineering Co., Ltd., approved by the Ministry of Foreign Trade and Economic Cooperation [2000] WJMZ No. 658 and the People's Government of Henan Province YGPZ [2000] No. 40.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Chongqing Shengkang Biotechnology Development Co., Ltd. General Legal Person 27443.87 17.44
2 Hong Kong Kekang Co., Ltd. General Legal Person 23989.40 15.24
3 Hong Kong Securities Clearing Company Ltd. Northbound Funds 2997.75 1.90
4 Shouchuang Securities Co., Ltd. Broker 1988.02 1.26
5 CSI 500 ETF Fund 1593.78 1.01
6 China Merchants Guozheng Biopharmaceutical Index Securities Investment Fund (LOF) Class A Fund 1445.91 0.92
7 Yongxin County Shengkang Xinkai Enterprise Management Consulting Center (Limited Partnership) General Legal Person 1350.20 0.86
8 ChinaAMC Guozheng Vaccine and Biotechnology Index Initiation Securities Investment Fund Class A Fund 46.33 0.03
9 Harvest CSI Vaccine and Biotechnology ETF Fund 45.18 0.03
10 Penghua Guozheng Vaccine and Biotechnology ETF Fund 36.44 0.02

5. Concept Sectors

  • Biological Vaccine
  • Gene Concept
  • Hepatitis Concept
  • Innovative Drug
  • Margin Trading & Securities Lending
  • Heavily Held by Brokers
  • High Dividend Stocks
  • Spin-off Listing
  • SME 100
  • SZSE 300
  • Technology 100
  • SME 300

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information